Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 52-59, 2023.
Artigo em Chinês | WPRIM | ID: wpr-984583

RESUMO

ObjectiveTo study the mechanism of Renshen Baidusan in regulating adenylate-activated protein kinase (AMPK)/Unc-51-like kinase 1 (ULK1) autophagy pathway to inhibit mucosal barrier damage in the mouse model of ulcerative colitis (UC). MethodSixty SD rats were randomized into normal, model, sulfasalazine enteric-coated tablets (0.312 5 g·kg-1, western medicine), and high-, medium-, and low-dose (31.2, 15.6, 7.8 g·kg-1, respectively) Renshen Baidusan groups. The UC model was induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS)/50% ethanol. The drugs were administrated by gavage for 2 weeks, and then the histopathological changes of the colon were examined. Real-time quantitative polymerase chain reaction was conducted to measure the mRNA level of AMP-activated protein kinase subunit alpha (AMPKα). Western blot was employed to determine the protein levels of closure protein (Occludin), compact linking protein-2 (Claudin-2), autophagy marker p62, microtubule-associated protein 1 light chain 3B (LC3B), phosphorylated AMPK (p-AMPK), and phosphorylated ULK1 (p-ULK1). ResultCompared with the normal group, the model group showed increased colon injury score (P<0.05), down-regulated mRNA level of AMPKα (P<0.05) and protein levels of p-AMPK, p-ULK1, and Occludin, decreased LC3Ⅱ/Ⅰ ratio (P<0.05), and up-regulated protein levels of p62 and Claudin-2 (P<0.05). Compared with the model group, all the doses of Renshen Baidusan lowered the colon injury score, up-regulated the mRNA level of AMPKα and the protein levels of p-AMPK, p-ULK1, and Occluding, increased LC3Ⅱ/Ⅰ ratio, and down-regulated the protein levels of p62 and Claudin-2. Moreover, the medium-dose group showed a significant intervention effect (P<0.05). ConclusionRenshen Baidusan can protect the intestinal mucosal barrier from damage, and the medium dose showed the best efficacy. It may activate the AMPK/ULK1 pathway to accelerate the transformation of LC3Ⅰ to LC3Ⅱ and promote the degradation of p62, so as to improve the function of Occludin and Claudin-2 and repair the mechanical damage of the intestinal barrier.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA